China Money Network
Login
Join

OrbiMed Leads $30M Round In Innovative Drug Developer Zai Lab

  • June 29, 2017 — 12:36 CST

This Data Is Locked!

This area is available only to Subscribers.

Healthcare-focused investment firm OrbiMed Asia Partners has led a US$30 million series C round in Zai Lab Ltd., a Shanghai-based innovative biopharmaceutical company. Chinese healthcare... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: